M&A Deal Summary

Ranbaxy Laboratories Acquires Terapia SA

On March 29, 2006, Ranbaxy Laboratories acquired life science company Terapia SA from Advent International for 324M USD

Acquisition Highlights
  • This is Ranbaxy Laboratories’ 1st transaction in the Life Science sector.
  • This is Ranbaxy Laboratories’ largest (disclosed) transaction.
  • This is Ranbaxy Laboratories’ 1st transaction in Romania.

M&A Deal Summary
Date 2006-03-29
Target Terapia SA
Sector Life Science
Buyer(s) Ranbaxy Laboratories
Sellers(s) Advent International
Deal Type Add-on Acquisition
Deal Value 324M USD

Target

Terapia SA

Cluj-Napoca, Romania
Terapia, then second-largest pharmaceuticals manufacturer in Romania, was a household name with an 80-year heritage.

Search 199,713 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Ranbaxy Laboratories

New Delhi, India
Category Company
Founded 1961
Sector Life Science
Employees15,300
DESCRIPTION

Ranbaxy Limited is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed and emerging 4 markets, many of which incorporate proprietary Novel Drug Delivery Systems and technologies developed at its own labs.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Add-on Acquisition) 1 of 1
Country (Romania) 1 of 1
Year (2006) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2007-10-03 Zenotech Laboratories

Hyderabad, India

Zenotech Laboratories Limited, a pharmaceutical specialty generic injectables company, manufactures bio-technology products.

Buy -

Seller(S) 1

SELLER

Advent International

Boston, Massachusetts, United States

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 1984
PE ASSETS 76.0B USD
Size Mega
Type Sector Agnostic
DESCRIPTION

Advent is a global private equity firm that targets investments in North America, Europe, Asia, and Latin America. Advent's emerging market efforts are concentrated in Central Europe and Latin America. Advent seeks transactions valued between $50 million and $5 billion and can commit up to $2 billion of equity capital per investment. Broad areas of interest include business & financial services, retail & consumer, technology, media, & telecoms, healthcare & life sciences, and industrial. Prospective transaction types include buyouts, growth capital financings, take privates, and recapitalizations. Advent was formed in 1984 and is based in Boston, Massachusetts.

DEAL STATS #
Overall 69 of 221
Sector (Life Science) 8 of 12
Type (Add-on Acquisition) 30 of 82
Country (Romania) 3 of 7
Year (2006) 4 of 15
Size (of disclosed) 36 of 52
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2006-02-21 Fada Pharma SA

Munro, Argentina

Fada Pharma SA is a major supplier to the nation’s leading healthcare institutions, such as Fleming, Fundacion Favaloro, Hospital Italiano, Hospital Britanico and the Ministry of Health. It also sells to nearly all major private hospitals in the Buenos Aires metropolitan area as well as to clinics and retail pharmacies across the country.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2006-05-01 CSU CardSystem SA

Barueri, Brazil

Largest independent credit card administrator in Brazil. IPO on BOVESPA (CARD3).

Sell -
Mergr

Product

Company

Legal